(RG7128) Slides/Data on all the New HCV drugs presented at the EASL 2011 meeting

Below is some of the most exciting data coming from the EASL , you can view all data at NATAP along with slides and commentary from Jules Levin.

Main Page At NATAP;
Eurpopean Association for the Study of the Liver
March 30th - April 3rd 2011
Berlin, Germany

New Slides at NATAP
Note Genotypes 1-4

First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1,2,3, and 4 patients: interim analysis from the JUMP-C trial

 Evolution of Treatment-Emergent Variants in Telaprevir Phase 3 Clinical Trials -
 
BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS (RAVS) ARE OBSERVED MORE FREQUENTLY IN HCV (GT1)-INFECTED PATIENTS WITH POOR RESPONSE TO PEGINTERFERON ALFA-2B/RIBAVIRIN -
 
Simplified Explanation of the Phase 3 Studies of HCV Protease Inhibitor Boceprevir -
 
Similar SVR Rates in IL28B CC, CT or TT Prior Relapser, Partial- or Null-responder Patients Treated with Telaprevir/Peginterferon/Ribavirin: Retrospective Analysis of the REALIZE Study -
 
Quadruple Therapy With BMS-790052, BMS-650032 and Peg-IFN/RBV for 24 Weeks Results in 100% SVR12 in HCV Genotype 1 Null Responders: "HCV infection can be cured without interferon & ribavirin: 2 orals BMS790052+BMS650032" -
 
PROTON Study: PSI-7977 QD with PEG/RBV: 12-week Safety, RVR, cEVR, & SVR12 in Treatment-naïve Patients with HCV GT2 or GT3 -
 
Activity of danoprevir plus low-dose ritonavir in combination with peginterferon alfa-2a (40KD) plus ribavirin in previous null responders -
.